Dental Care Clinics in Marblehead, MA Accepting Medicare
9 Dental Care Clinics found. Showing 1 - 9
 Dr Jeffrey R Dornbush Pss Pc Dentist - Prosthodontics Medicare: Not Enrolled in Medicare Practice Location: 210 Humphrey Street, Marblehead, MA 01945 Phone: 781-639-0700 Fax: 781-639-8060 |
James U Rice Dmd Pc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 2 Hooper Street, Marblehead, MA 01945 Phone: 781-631-3162 Fax: 781-631-2578 |
Group One Smiles Pllc Dentist - Pediatric Dentistry Medicare: Not Enrolled in Medicare Practice Location: 210 Humphrey St, Marblehead, MA 01945 Phone: 617-909-5459 |
Yvette Glina, Dds, Llc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 1 Sheldon Rd, 62 Humphrey Street Entrance, Marblehead, MA 01945 Phone: 781-631-3400 Fax: 781-631-3464 |
Cognata J Dmd, Michael&barone Dentist - Pediatric Dentistry Medicare: Not Enrolled in Medicare Practice Location: 210 Humphrey St, Suite 106, Marblehead, MA 01945 Phone: 781-639-4500 Fax: 781-639-9181 |
Marblehead Pediatric Dentistry And Braces Pc Dentist - Pediatric Dentistry Medicare: Not Enrolled in Medicare Practice Location: 210 Humphrey St, Marblehead, MA 01945 Phone: 781-639-4500 |
Bruce P Bolen Dmd Llc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 2 Hooper St, Marblehead, MA 01945 Phone: 781-631-3799 |
Marblehead Smile Design And Family Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 11 Atlantic Ave, 2nd Floor, Marblehead, MA 01945 Phone: 781-631-2207 Fax: 781-631-2209 |
Marblehead Dental Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 37 School St, Marblehead, MA 01945 Phone: 781-631-7950 Fax: 781-631-7953 |
News Archive
3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.
Oxaliplatin and bevacizumab disappoint for rectal cancer
The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results.
Purdue University-led analysis finds that carotenoid levels in breast milk differ by country, dietary habits
A Purdue University-led analysis of breast milk concludes that levels of health-promoting compounds known as carotenoids differ by country, with the U.S. lagging behind China and Mexico, a reflection of regional dietary habits.
Study finds gaps in opioid use disorder treatment during COVID shutdowns
In the early months of the COVID-19 pandemic, visits to the doctor declined dramatically. One group of patients that appears to have weathered this trend are those who were already being treated for opioid use disorder.
Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has engaged the Numoda Corporation, a leading information, process and logistics management company, to oversee the Phase III clinical trial of DAVANAT and 5-FU compared with the standard of care in the treatment of patients with advanced, metastatic colorectal cancer.
› Verified 7 days ago